Nicola Bisek

This inventor holds 13 USPTO granted patents and 18 published patent applications, plus 6 CIPO patents and 5 EPO patents. Top assignees: Ascendis Pharma A/s, Ascendis Pharma Inc., Ascendis Pharma Oncology Division A/s. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicola Bisek. Retrieved from https://idiyas.com/inventor/nicola-bisek

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 18)

% Patents Active = 100.0

CIPO Patents = 6 (Patent Applications = 19)

EPO Patents = 5 (Patent Applications = 26)

Average Co-Inventor Count = 5.4

ph-index = 2

Forward Citations = 16(Granted Patents)

Company Filing History:

Ascendis Pharma Oncology Division A/s

patents

4. 1 out of 1

Ascendis Pharma Ophthalmology Division A/s

patent

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12648997 - Treatment of infections (2026-06-09),

2. 12594345 - Degradable hyaluronic acid hydrogels (2026-04-07),

3. 12565525 - IL-2 Conjugates (2026-03-03),

4. 12246070 - Hydrogel cross-linked hyaluronic acid prodrug compositions and methods (2025-03-11),

5. 11896671 - Conjugation method for carrier-linked prodrugs (2024-02-13),

6. 11642415 - Hydrogel cross-linked hyaluronic acid prodrug compositions and methods (2023-05-09),

7. 11633487 - Prodrugs comprising an aminoalkyl glycine linker (2023-04-25),

8. 11298427 - Prodrugs comprising a pyroglutamate linker (2022-04-12),

9. 10729778 - Carrier-linked treprostinil prodrugs (2020-08-04),

10. 10519226 - VEGF neutralizing prodrugs for the treatment of ocular conditions (2019-12-31),

11. 10040850 - Protecting group comprising a purification tag (2018-08-07),

12. 9855340 - Hydrogel prodrugs (2018-01-02),

13. 9561287 - Carrier-linked treprostinil prodrugs (2017-02-07),

Title: Inventor Spotlight: Nicola Bisek

Introduction

Nicola Bisek is an innovative inventor based in Heidelberg, Germany, renowned for her contributions to the field of biomedical engineering and pharmaceutical sciences. With a robust portfolio that includes ten patents, Bisek's work is focused on developing advanced hydrogel systems for therapeutic applications.

Latest Patents

Among her most recent innovations, Bisek has patented "Hydrogel Cross-Linked Hyaluronic Acid Prodrug Compositions and Methods." This groundbreaking invention involves hydrogel prodrug compositions that incorporate cross-linked hyaluronic acid (HA) designed to release drugs under physiological conditions, making significant strides in treating ocular conditions. Another of her notable patents is the "Conjugation Method for Carrier-Linked Prodrugs," which consists of advanced reagents aimed at synthesizing carrier-linked prodrugs. These compositions have the potential to revolutionize targeted drug delivery in various medical applications.

Career Highlights

Nicola Bisek has held pivotal roles in prominent companies throughout her career, including Ascendis Pharma A/S and the Ascendis Pharma Ophthalmology Division A/S. Her work in these organizations has facilitated the development of innovative therapeutic solutions, particularly in the field of ocular health.

Collaborations

Throughout her career, Bisek has collaborated with esteemed professionals such as Harald Rau and Thomas Knappe. These collaborations have enriched her research and have contributed to the successful development of her patented technologies.

Conclusion

With a remarkable track record of inventions, Nicola Bisek continues to push the boundaries of biomedical innovation. Her patented developments not only showcase her creative ingenuity but also highlight her commitment to improving patient outcomes through advanced drug delivery systems. As she continues her groundbreaking work, the impact of her inventions is expected to grow, leading to significant advancements in medical treatments.

Profile summary based on public USPTO records.